# Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

> **NCT05438303** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 59 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** AZD9833
- **DRUG:** Midazolam
- **DRUG:** Omeprazole
- **DRUG:** Dabigatran Etexilate
- **DRUG:** Celecoxib

## Key facts

- **NCT ID:** NCT05438303
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-13
- **Primary completion:** 2022-12-13
- **Final completion:** 2022-12-13
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2023-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05438303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05438303, "Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05438303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*